Last date to be eligible to participate in buyback is April 16, 2026.

The Aurobindo Pharma Buyback 2026 is a Tender Offer.

Sorry, the Aurobindo Pharma Buyback 2026 timelines are not available at this time.

Sorry, the Aurobindo Pharma Buyback 2026 timelines are not available at this time.

The Aurobindo Pharma Buyback 2026 is being offered at Rs ₹1475 per share.

The record date for the Aurobindo Pharma Buyback 2026 is April 17, 2026.

The issue size of Aurobindo Pharma Buyback 2026 is 54,23,728 equity shares at ₹1475 per share aggregating up to ₹800.00 Crores.

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

Return surplus funds to shareholders and enhance overall shareholder returns.
Optimise the Company’s capital structure.
Improve financial ratios such as earnings per share and return on equity.
Enhance long-term shareholder value.
Provide shareholders the flexibility to either participate in the Buyback for cash or retain their shareholding and benefit from an increased post-buyback ownership.

Letter of Offer

All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.

The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.

The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.

The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.

The Aurobindo Pharma Buyback 2026 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one’s need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.